Related Experiment Video
Updated: Feb 27, 2026

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus
Linde A Miles1, Laura N Burga2, Eric E Gardner1
1Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abstract:
Seneca Valley virus (SVV) is an oncolytic picornavirus with selective tropism for neuroendocrine cancers. It has shown promise as a cancer therapeutic in preclinical studies and early-phase clinical trials. Here, we have identified anthrax toxin receptor 1 (ANTXR1) as the receptor for SVV using genome-wide loss-of-function screens. ANTXR1 is necessary for permissivity in vitro and in vivo. However, robust SVV replication requires an additional innate immune defect. We found that SVV interacts directly and specifically with ANTXR1, that this interaction is required for SVV binding to permissive cells, and that ANTXR1 expression is necessary and sufficient for infection in cell lines with decreased expression of antiviral IFN genes at baseline. Finally, we identified the region of the SVV capsid that is responsible for receptor recognition using cryoelectron microscopy of the SVV-ANTXR1-Fc complex. These studies identify ANTXR1, a class of receptor that is shared by a mammalian virus and a bacterial toxin, as the cellular receptor for SVV.
Insights
Seneca Valley virus (SVV) uses anthrax toxin receptor 1 (ANTXR1) to infect cancer cells. This virus, a promising cancer therapeutic, requires ANTXR1 and an innate immune defect for robust replication.
Area of Science:
- Virology
- Oncology
- Immunology
Background:
- Seneca Valley virus (SVV) is an oncolytic picornavirus targeting neuroendocrine cancers.
- SVV demonstrates therapeutic potential in preclinical and early clinical settings.
Purpose of the Study:
- Identify the cellular receptor for Seneca Valley virus (SVV).
- Elucidate the mechanism of SVV entry and replication.
Main Methods:
- Genome-wide loss-of-function screens to identify SVV receptors.
- In vitro and in vivo permissivity assays.
- Cryoelectron microscopy of the SVV-ANTXR1-Fc complex.
Main Results:
- Anthrax toxin receptor 1 (ANTXR1) identified as the cellular receptor for SVV.
- ANTXR1 is essential for SVV binding and infection in permissive cells.
- Robust SVV replication necessitates an additional innate immune defect, such as impaired interferon gene expression.
Conclusions:
- ANTXR1 is the primary receptor for SVV, mediating viral entry.
- SVV leverages a receptor shared with a bacterial toxin for cellular entry.
- Understanding SVV-ANTXR1 interaction is crucial for developing SVV-based cancer therapies.
More Related Videos
13:12Transsynaptic Tracing from Peripheral Targets with Pseudorabies Virus Followed by Cholera Toxin and Biotinylated Dextran Amines Double Labeling
Published on: September 14, 2015
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Related Concept Videos
Receptor-mediated Endocytosis
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Receptor-mediated Endocytosis
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Viruses of Archaea